Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes.
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes.
复制标题
DOI：
10.2337/ds16-0026
复制
发表时间：
2017-08-01
期刊：
影响因子：
--
通讯作者：
Hinnen, Deborah
中科院分区：
文献类型：
--
作者：
Hinnen, Deborah
近年来，胰升糖素系统已成为治疗2型糖尿病的重要靶点，而胰升糖素样肽1(GLP-1)因其降血糖作用而备受关注。在一些2型糖尿病患者中，口服营养物质的生理反应会降低，但GLP-1受体激动剂的使用可能会增强这种反应。目前在美国被批准用于治疗2型糖尿病的GLP-1受体激动剂包括艾塞那肽(每天给药两次)、利拉鲁肽和利塞那肽(每天给药一次)，以及每周一次的艾塞那肽缓释剂、阿尔比鲁肽和度那肽。这些药物已被证明可以降低A1C(降低0.8-1.6%)、体重(降低1-3公斤)、血压和血脂。GLP-1受体激动剂与低血糖风险有关，最常见的不良反应是胃肠道反应。适当的患者选择和教育可以帮助实现积极的治疗结果。
The incretin system has become an important target in the treatment of type 2 diabetes in recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects. The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with type 2 diabetes but may be augmented by administration of GLP-1 receptor agonists. The GLP-1 receptor agonists currently approved in the United States for the treatment of type 2 diabetes include exenatide (administered twice daily), liraglutide and lixisenatide (administered once daily), and the once-weekly agents exenatide extended-release, albiglutide, and dulaglutide. These agents have been shown to reduce A1C (by 0.8-1.6%), body weight (by 1-3 kg), blood pressure, and lipids. GLP-1 receptor agonists are associated with a low risk of hypoglycemia, and the most common adverse effects are gastrointestinal. Proper patient selection and education can assist in achieving positive treatment outcomes.